Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats

Tian, Xiaozhu; Chen, Yong; Bai, Lu; Luo, Pan; Du, Xue–Jing; Chen, Qiang; Tian, Xin-min

doi:10.1016/j.ejphar.2014.11.025

Cited by 9 publications

(5 citation statements)

References 26 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher vasoreactivity in BMS patients was reported by Heckmann et al in a study on oral mucosal blood flow in BMS patients [29]. It has been proven that opiorphin has cardiovascular effects mediated through the renin-angiotensin system, as it rises the blood pressure and pulse when injected intravenously [30][31][32]. Curiously, BMS compatible symptoms were previously associated with antihypertensive drugs that act upon the angiotensin-renin system, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers or antagonists [33].…”

Section: Discussionmentioning

confidence: 99%

Opiorphin in burning mouth syndrome patients: a case-control study

2016

View full text Add to dashboard Cite

Opiorphin may be a measurable biomarker for chronic pain, which could help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could serve as a universal objective indicator of painful conditions. Since opiorphin may also reflect emotional and socio-relational imbalances occurring with BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin's involvement in pain pathways could contribute to developing new clinical diagnostic methods for BMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Opiorphin in burning mouth syndrome patients: a case-control study

2016

View full text Add to dashboard Cite

show abstract

“…These effects are mediated through the renin-angiotensin system, the sympathetic ganglia and adrenal medulla. 16 A study assessing the salivary concentration of opiorphin level before and after administration of local anesthesia (LA) showed a significant difference in the levels of salivary opiorphins ranging from 5.96-14.49ng/ml before and after LA administration, suggesting the possible action of local anesthetics on the ENKs. 17 In spite of the captivating leads of opiorphin peptide, its pharmaceutical development is hindered by its low stability, typical of N-terminal glutamine peptides.…”

Section: Opiorphin: the Promising Alternativementioning

confidence: 99%

An analgesic to bridge the gap between Narcotics and NSAIDs: opiorphin

Sujatha¹,

Priyadharshini²,

Nejad³

et al. 2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Pain management is an all-time challenge in dentistry. Discontent to pain management is a concern among patients and professionals. Unrelieved pain affects physical and mental well-being contributing to delayed recovery, psychological distress and anxiety. Studies have revealed that chronic pain interferes with normal daily chores of the individual like exercise, sleep, social life and lifestyle. At one end of pain management spectrum are Non-steroidal anti-inflammatory drugs (NSAIDs) while at the other end are the opioids. These drugs are not without constituent side effects. The quest is for new analgesics with potent and long term analgesia with minimal or no side effects. An analgesic that is intermediate in this spectrum is the need of the hour. Opiorphin is an endogenous peptide isolated from human saliva. Opiorphin produces analgesia, by inhibiting enkephalin (ENK) metabolizing enzymes, thus increasing the half-life of circulating ENKs. Apart from being a potent analgesic it can also be a potential biomarker for various systemic and psychosocial disorders. This review focuses on the pharmacological effects of opiorphin and its potential role as a biomarker in various disease conditions.

show abstract

“…Sufficient evidence suggests that HO protects enkephalins from enzymolysis both in vivo and in vitro ( Wisner et al, 2006 ; Tian et al, 2009 ). HO has been implicated in several biological actions in mice, including analgesic activity, penile erection, and cardiovascular functions ( Tong et al, 2008 ; Tian et al, 2009 ; Tian et al, 2015 ). Our previous study suggests that HO enhances colonic contraction by activating MOR and DOR in vitro , which is attributable to the inhibition of enkephalins degradation ( Tian et al, 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system

Luo

Gao

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The opioid system plays a crucial role in maintaining gastrointestinal homeostasis. Endogenous opioid peptide enkephalins have anti-inflammatory effect and participate in the treatment of inflammatory bowel diseases (IBDs). Here, we investigated the effect of natural enkephalinase inhibitor human opiorphin (HO) on dextran sodium sulfate (DSS)-induced colitis in mice. Our results showed that central administration of HO attenuated DSS-induced colitis, as indicated by the reduction of disease activity index (DAI) scores, macroscopic scores, histological scores, and the myeloperoxidase (MPO) activity. Moreover, HO alleviated DSS-induced inflammation by decreasing inflammatory cytokines TNF-α, IL-6, and IL-1β, and increasing anti-inflammatory cytokine IL-10 in both serum and colon tissues in DSS-treated mice. The potential anti-inflammatory effect of HO at a dose of 40 μg/kg was observed as evidenced by a decrease in nuclear factor κB (NF-κB) p65, toll-like receptor-4 (TLR-4), iNOS, and COX-2. HO also improved intestinal barrier function by enhancing the expression of tight junction proteins. Furthermore, HO treatment significantly inhibited activities of neutral endopeptidase (NEP) and aminopeptidase N (APN), elevated serum enkephalins concentrations, and increased expressions of mu and delta opioid receptors. In addition, pretreatment with opioid receptor antagonist naloxone hydrochloride (NH) compromised the protective effect of HO and aggravated colitis symptoms, as indicated by inhibited anti-inflammatory effects, disrupted intestinal barrier function, and decreased opioid receptor activity. In conclusion, these data indicate that HO protects against DSS-induced colitis by inhibiting TLR4/NF-κB pathway activation and improving intestinal barrier function through activation of the endogenous opioid system. Therefore, targeting the opioid system with peptidase inhibitors intervention would be a novel strategy in the therapy of IBD.

show abstract

Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats

Cited by 9 publications

References 26 publications

Opiorphin in burning mouth syndrome patients: a case-control study

Opiorphin in burning mouth syndrome patients: a case-control study

An analgesic to bridge the gap between Narcotics and NSAIDs: opiorphin

Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system

Contact Info

Product

Resources

About